Publicaciones en colaboración con investigadores/as de Essen University Hospital (17)

2023

  1. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 6, pp. 1137-1154

  2. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692

  3. Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna

    Annals of Oncology

  4. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials

    Annals of Oncology, Vol. 34, Núm. 1, pp. 70-77

  5. Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study

    European Journal of Cancer, Vol. 190

2022

  1. Current practice in proton therapy delivery in adult cancer patients across Europe

    Radiotherapy and Oncology, Vol. 167, pp. 7-13

2021

  1. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

    The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501

2020

  1. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

    ESMO Open, Vol. 5, Núm. 3

2019

  1. Comparison of six commercial serum exosome isolation methods suitable for clinical laboratories. Effect in cytokine analysis

    Clinical Chemistry and Laboratory Medicine, Vol. 57, Núm. 10, pp. 1539-1545

  2. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy

    European Journal of Cancer, Vol. 117, pp. 99-106

  3. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428

2016

  1. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

    Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052

2015

  1. Treatment algorithms in stage IV melanoma

    American Journal of Therapeutics

2013

  1. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck

    European Journal of Cancer, Vol. 49, Núm. 13, pp. 2877-2883

2009

  1. Immunotherapy of distant metastatic disease

    Annals of Oncology, Vol. 20, Núm. SUPPL. 4

2006

  1. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia

    Journal of the National Cancer Institute, Vol. 98, Núm. 4, pp. 273-284

1995

  1. Intraoperative strahlentherapie inklusive afterloadingverfahren in der gastrointestinalen chirurgie

    Viszeralmedizin: Gastrointestinal Medicine and Surgery, Vol. 11, Núm. 2, pp. 153-159